Health Checkup Packages Under Scrutiny as Experts Call for Evidence‑Based Testing

In a recent segment of the India Today Healthtech Summit, three leading medical professionals – Dr Arvind Lal, Dr Harsh Mahajan and Prof Dr Navin Dang – dissected the burgeoning market of health‑checkup packages and the science behind essential diagnostic tests. Their discussion, captured in a video report released on 30 October 2026, highlighted the tension between commercial health‑screening offers and the need for medically justified testing. The experts warned that indiscriminate testing can strain both patients and the public health system, while underscoring how targeted diagnostics, when ordered under proper clinical guidance, can improve outcomes in chronic disease management, cancer detection and cardiovascular risk assessment. This article unpacks their key points, situates them within India’s regulatory framework, and examines the implications for patients, insurers, and the broader health‑tech ecosystem.

Why Not All Tests Are Necessary: The Core Argument

Dr Lal opened the conversation by questioning the premise that “more tests equal better health.” He argued that many commercial health‑checkup packages bundle a wide array of investigations that lack a clear evidence‑based rationale for asymptomatic individuals. The panel noted that the right test, at the right time, under medical guidance, can indeed be life‑saving, but the opposite – unnecessary testing – can lead to false positives, anxiety, and downstream costs.

Dr Mahajan reinforced this view by pointing out that the proliferation of “one‑size‑fits‑all” packages often reflects market‑driven incentives rather than clinical need. He emphasized that preventive health strategies should be anchored in risk stratification, not blanket testing. The experts agreed that clinicians must assess individual risk factors – age, family history, lifestyle – before ordering panels that include, for example, extensive tumor markers or genetic screens that may have limited predictive value for the average population.

Prof Dr Dang added a public‑health perspective, noting that the Ministry of Health and Family Welfare has issued guidelines on essential tests for specific age groups and risk categories. He cautioned that deviation from these guidelines without a clear justification can dilute the effectiveness of national screening programmes, such as those for diabetes and hypertension, which already face resource constraints.

Collectively, the panel’s stance aligns with the Indian Council of Medical Research’s (ICMR) emphasis on evidence‑based diagnostics. Their message is clear: patients should seek tests that are recommended by authoritative bodies and prescribed by qualified physicians, rather than relying on marketing brochures.

Decoding Essential Health Tests: What Should Be Prioritized?

The trio identified a core set of investigations that form the backbone of preventive health monitoring in India. Dr Lal highlighted routine blood glucose measurement, lipid profile, blood pressure monitoring and basic renal function tests as the minimum required for adults over 30 years, especially given the rising burden of non‑communicable diseases (NCDs) in the country.

Dr Mahajan expanded on cardiovascular risk assessment, recommending that individuals with a family history of heart disease or known risk factors undergo ECG and, where indicated, stress testing. He stressed that these tests should be ordered after a clinical evaluation rather than as part of a generic “heart health” package.

Prof Dr Dang turned the focus to cancer screening, noting that population‑level programmes in India currently target breast, cervical and oral cancers. He warned against the inclusion of extensive tumor marker panels in routine health checks, as many such markers lack sufficient sensitivity and specificity for early detection in asymptomatic individuals.

All three experts concurred that the selection of tests must be guided by national screening protocols issued by the Ministry of Health, the National Cancer Registry Programme, and the ICMR, ensuring alignment with the country’s public‑health priorities and resource allocation.

The Rise of Predictive and Preventive Testing: Opportunities and Pitfalls

The discussion moved to the emerging field of predictive medicine, where genetic and genomic tests promise to identify disease susceptibility before clinical manifestation. Prof Dr Dang explained that while genome testing holds promise for personalized risk assessment, its current utility in the Indian context is limited by cost, interpretative challenges, and a lack of robust population‑specific reference data.

Dr Mahajan cautioned that the commercial availability of direct‑to‑consumer genetic tests can create a false sense of security or alarm, especially when results are not interpreted by qualified clinicians. He urged the Ministry of Health to develop clear guidelines on the clinical integration of genomic data, akin to the regulatory oversight exercised by the Central Drugs Standard Control Organization (CDSCO) for diagnostic kits.

Dr Lal highlighted the role of artificial intelligence (AI) in augmenting diagnostic accuracy, particularly in imaging and pattern recognition. He noted that AI‑driven tools can help triage patients and flag abnormalities in radiographs or pathology slides, potentially reducing the need for redundant testing. However, he stressed that AI algorithms must be validated on Indian datasets to avoid bias and ensure reliability.

Overall, the panel recognized the transformative potential of predictive technologies but warned that premature adoption without rigorous validation could exacerbate inequities and lead to unnecessary interventions.

Antimicrobial Resistance and Diagnostic Stewardship

A recurring theme in the summit was the link between diagnostic practices and antimicrobial resistance (AMR). Dr Lal underscored that indiscriminate ordering of bacterial cultures, such as the Widal test for typhoid, can result in over‑prescription of antibiotics when results are misinterpreted or when false‑positive results drive unnecessary treatment.

Prof Dr Dang emphasized that accurate, timely diagnostics are essential to curb AMR, a priority highlighted in the National Action Plan on Antimicrobial Resistance. He advocated for the use of rapid, point‑of‑care tests that can differentiate bacterial from viral infections, thereby guiding appropriate antimicrobial therapy.

Dr Mahajan called for stronger diagnostic stewardship programmes within hospitals and private labs, urging the Ministry of Health to enforce standards for test ordering, similar to the stewardship frameworks applied to antibiotic prescribing. He suggested that labs should provide decision‑support tools that help clinicians choose the most relevant tests based on clinical presentation.

The experts collectively urged that improving diagnostic accuracy is a cornerstone of AMR mitigation, and that patients should be educated about the risks of unnecessary antibiotic use driven by unwarranted testing.

Selecting the Right Diagnostic Lab: Quality and Accreditation

Beyond the choice of tests, the panel addressed the importance of selecting reputable diagnostic laboratories. Dr Mahajan highlighted that accredited labs, such as those certified by the National Accreditation Board for Testing and Calibration Laboratories (NABL), adhere to standardized quality protocols, ensuring reliable results.

Prof Dr Dang noted that many private labs market “premium” packages that bundle numerous tests at attractive prices, but the quality of individual assays can vary. He recommended that patients verify a lab’s accreditation status, check for participation in external quality assessment schemes, and seek referrals from trusted physicians.

Dr Lal pointed out that the rise of digital health platforms has made it easier to compare lab services online, but cautioned that price comparison should not eclipse quality considerations. He urged the Ministry of Health to strengthen public awareness campaigns about lab accreditation and to promote a transparent rating system for diagnostic facilities.

The consensus was clear: informed lab selection is as crucial as test selection, and adherence to accreditation standards protects patients from inaccurate results that can lead to misdiagnosis and inappropriate treatment.

Implications for Indian Stakeholders: Policy, Patients and the Health‑Tech Industry

For policymakers, the panel’s insights call for tighter regulation of health‑checkup packages. The Ministry of Health could consider mandating that commercial packages disclose the clinical justification for each test, aligning offerings with national screening guidelines. Such transparency would empower consumers and curb the proliferation of unnecessary investigations.

Patients stand to benefit from greater awareness of evidence‑based testing. By consulting qualified physicians and verifying lab accreditation, individuals can avoid the financial and emotional costs of false positives and unnecessary follow‑up procedures. Consumer education initiatives, possibly led by the Ministry of Health in partnership with professional bodies such as the Indian Medical Association, could disseminate clear guidance on essential tests.

The health‑tech sector, including companies like Dr Lal PathLabs and Mahajan Imaging, must balance innovation with responsibility. While AI‑driven diagnostics and expanded testing menus can drive growth, firms should align product development with regulatory standards and ensure that new tests are validated for the Indian population. Collaboration with research institutions like the ICMR and academic hospitals (AIIMS, PGIMER) can facilitate evidence generation and foster trust.

In sum, the India Today Healthtech Summit highlighted a pivotal moment for India’s diagnostic landscape. By anchoring test selection in clinical need, reinforcing lab quality, and integrating emerging technologies responsibly, the nation can enhance preventive health outcomes while safeguarding resources and public trust.

By Dr. Raj Patel, Staff Writer

This article was produced with AI-assisted research and editorial support. Reporting is based on the source material cited below. Sources: India Today video report (30 October 2026); India Today; Global1.News